—New Proteomic Analyses of Phase 2a
Liver Fibrosis Clinical Data Show Consistent and Significant
Improvements in Liver-related Pathology Pathways After
Treatment with CM-101—
—Oral Presentation of Proteomic Analyses in
PSC Patients Provides Further Evidence that CCL24 Is a Key Driver
of the Inflammatory and Fibrotic Processes Underlying PSC and
Other Disorders—
TEL
AVIV, Israel, Nov. 13,
2023 /PRNewswire/ -- Chemomab Therapeutics Ltd.
(Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company
focused on the discovery and development of innovative therapeutics
for fibro-inflammatory diseases with high unmet need, today
reported on its oral and poster presentations at AASLD's The Liver
Meeting® 2023, being held November 10-14, 2023.
In an oral presentation by Ilan
Vaknin, PhD, Chemomab's Vice President of R&D, analysis
of serum samples from patients with primary sclerosing cholangitis
(PSC) provided further evidence that the soluble protein CCL24 is
associated with key inflammatory and fibrotic pathways implicated
in the liver damage characterizing PSC.1
Chemomab's first-in-class monoclonal antibody CM-101 is
designed to neutralize CCL24 and normalize PSC's fibro-inflammatory
disease processes. CM-101 is currently in a Phase 2 trial in PSC
patients that is advancing towards completion of enrollment. A
top-line data readout is expected in the second half of next year.
There currently are no FDA-approved therapies for this devastating,
often lethal disease.
A poster presentation hosted by Matt
Frankel, MD, Chief Medical Officer of Chemomab, described
key findings from proteomic analyses of serum samples at baseline
and after 16 weeks of treatment with CM-101 from the company's
Phase 2a liver fibrosis trial in patients with nonalcoholic
steatohepatitis (NASH).2 These analyses demonstrated
consistent and significant reductions in liver-related pathology
pathways that lead to liver damage, activation of liver fibroblasts
and liver steatosis. Moreover, proteomic analysis showed that
CM-101 treatment led to significant downregulation in multiple
immune-related pathways, along with an increase in metabolic
pathways associated with improved glucose and fat metabolism. The
study also indicated that CM-101 has a strong and specific target
engagement profile for CCL24.
"These new data using advanced proteomic analytic tools add to
the extensive body of evidence that CCL24 is a major driver of
fibrotic and inflammatory processes underlying PSC and other
fibrotic liver diseases," said Adi
Mor, PhD, co-founder, Chief Executive Officer and Chief
Scientific Officer of Chemomab. "These data also confirm that key
features of PSC are uniquely associated with high levels of CCL24.
We are rapidly advancing towards completion of patient enrollment
in our Phase 2 PSC trial and look forward to a top-line data
readout in the coming year."
The PSC oral presentation describes advanced proteomics analyses
of serum samples from PSC patients and healthy controls. The study
showed that PSC disease-related pathways, upstream disease
regulators and PSC-related toxicity functions are elevated in
patients with high CCL24 levels. The analysis also revealed the
unique association of CCL24 with PSC mechanisms, with no similar
association with two other members of the same subfamily (CCL11 and
CCL26) that share the same receptor as CCL24. The authors note that
this study provides further evidence of the critical role of CCL24
in the pathogenesis of PSC, highlighting its unique association
with disease-related pathways.
Copies of Chemomab's oral and poster presentations from AASLD's
The Liver Meeting® 2023 are available at
www.chemomab.com/r-d/
1-Serum proteomics reveals unique association of CCL24 with
disease-related pathways and signatures in primary sclerosing
cholangitis, T Snir, R Greenman, R Aricha, J Lawler, F
Saffioti, D Thorburn, M Pinzani, A Mor, I Vaknin. Session--Breaking
the Chains of Cholestatic Liver Injury: Advancements and Promising
Treatment Strategies
2- CM-101, a CCL24 neutralizing antibody, showed
improvements in inflammatory, fibrotic, and metabolic pathways in
patients with NASH: Proteomics analysis of a Phase 2a study, R
Aricha, T Snir, I Vaknin, J Lawler, A Mor, M Frankel
Forward Looking Statements
This press release
contains "forward-looking statements" within the meaning of the
Private Securities Litigation Reform Act. These forward-looking
statements include, among other things, statements regarding the
clinical development pathway for CM-101; the length, duration and
impact of the war in Israel
on Chemomab's business and operations; the future
operations of Chemomab and its ability to successfully
initiate and complete clinical trials and achieve regulatory
milestones; the nature, strategy and focus of
Chemomab; the development and commercial potential and
potential benefits of any product candidates of
Chemomab; and that the product candidates have the potential
to address high unmet needs of patients with serious
fibrosis-related diseases and conditions. Any statements contained
in this communication that are not statements of historical fact
may be deemed to be forward-looking statements. These
forward-looking statements are based upon Chemomab's
current expectations. Forward-looking statements involve
risks and uncertainties. Because such statements deal with future
events and are based on Chemomab's current
expectations, they are subject to various risks and uncertainties
and actual results, performance or achievements of Chemomab
could differ materially from those described in or implied by
the statements in this presentation, including those found under
the caption "Risk Factors" and elsewhere in Chemomab's
filings and reports with the SEC. Chemomab
expressly disclaims any obligation or undertaking to release
publicly any updates or revisions to any forward-looking statements
contained herein to reflect any change in Chemomab's
expectations with regard thereto or any change in events,
conditions or circumstances on which any such statements are based,
except as required by law.
About Chemomab Therapeutics Ltd.
Chemomab is a
clinical stage biotechnology company developing innovative
therapeutics for fibro-inflammatory diseases with high
unmet need. Based on the unique and pivotal role of CCL24 in
promoting fibrosis and inflammation, Chemomab
developed CM-101, a monoclonal antibody designed to
neutralize CCL24 activity. In preclinical and clinical studies,
CM-101 appears safe, with the potential to treat multiple severe
and life-threatening fibro-inflammatory
diseases. Chemomab has reported encouraging
results from three clinical trials of CM-101 in patients, including
a Phase 1b trial in NAFLD
patients, a Phase 2a liver fibrosis trial in NASH patients
and an investigator-initiated study in patients with severe lung
injury. The CM-101 program for the treatment of systemic sclerosis
is Phase 2-ready and a Phase 2 trial in primary sclerosing
cholangitis patients is ongoing, with topline
data expected in the second half of 2024. For more
information about Chemomab, visit
chemomab.com.
Contacts:
Media and Investors:
Barbara Lindheim
Consulting Vice President, Investor & Public
Relations,
Strategic
Communications
Phone: +1
917-355-9234
barbara.lindheim@chemomab.com
IR@chemomab.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/chemomab-presents-new-clinical-data-supporting-cm-101s-anti-fibroticanti-inflammatory-activity-in-patients-with-liver-fibrosis-and-new-data-highlighting-unique-association-of-its-ccl24-target-with-key-psc-pathways-at-aaslds-the-301985772.html
SOURCE Chemomab Therapeutics, Ltd.